News

Hims & Hers’ ugly split with Wegovy maker weighs on the telehealth company’s future
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
InvestorsHub on MSN3d
Hims & Hers Shares Gain on Plans for Canadian Launch Featuring Generic Semaglutide
Hims & Hers Health (NYSE:HIMS) shares climbed 2% on Wednesday following the announcement of its planned market entry into ...
Stocktwits on MSN2d
Hims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent Expires
Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...
StockStory.org on MSN3d
Hims & Hers Health (HIMS) Stock Is Up, What You Need To Know
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...
Market Voices: Copper tariffs, mortgage volumes rise, Hims & Hers
Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...
Hims & Hers Health: Unlocking A $6 Billion Future
Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...
Explore more
Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers
U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.